That is a sizeable increase on Pfizer's September offer of $47.50 upfront and $22.50 in CVRs, which combined to give a deal ...

Prostate Cancer UK started a £42 million ($55 million), large-scale study called TRANSFORM last year to test that MRI-refined ...

The FDA has proposed a radical change to the regulatory requirements for bringing biosimilars to market, in a bid to accelerate the rollout of cheaper versions of off-patent biologic drugs. Draft ...

At San Diego-based CDMO and CRO Abzena, Geoffrey M Glass has stepped into the CEO role. Glass has served as Chairman of the ...

MSD, known as Merck & Co in the US and Canada, licensed rights to Lenvima in 2018 in a near-$6 billion deal aimed at ...

The news on vaccines was not so good, as declining sales of shingles shot Shingrix in the US and China pegged back growth to ...

CSL's already depressed share price sank further on the news of the delay, which chairman Dr Brian McNamee said was related ...

Eli Lilly and tech giant NVIDIA have joined forces on an ambitious plan – building the most powerful AI-powered supercomputer ...

At ESMO this year, AstraZeneca presented final overall survival results from the MATTERHORN Phase III Trial for patients with ...

Nex-z is one of two late-stage projects on the go at Intellia, a specialist in CRISPR gene-editing co-founded by Nobel Prize ...

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ilya Burkov, global head of healthcare & life sciences ...

BBP-418 hit the mark in the phase 3 FORTIFY trial by achieving a significant increase in glycosylated alpha-dystroglycan (αDG), which is impaired in LGMD and causes muscle wasting, initially in the ...